Back to results
US 2019/0167704 A1Published application
Therapeutic combinations comprising anti-folr1 immunoconjugates
AssigneeImmunoGen, Inc.
InventorsJose PONTE, Jan PINKAS, Rodrigo R. RUIZ-SOTO
Life of this patent
Estimating the term…
Abstract
Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
Claims28
1-104. (canceled)
A method for treating a patient having cancer comprising administering to said patient in need thereof:
- (a) an immunoconjugate that binds to folate receptor 1 (FOLR1), wherein said immunoconjugate comprises
- (i) an anti-FOLR1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) complementary determining region (CDR)1 sequence of SEQ ID NO:9, a VH CDR2 sequence of SEQ ID NO:10, and a VH CDR3 sequence of SEQ ID NO:12, and a light chain variable region (VL) CDR1 sequence of SEQ ID NO:6, a VL CDR2 sequence of SEQ ID NO:7, and a VL CDR3 sequence of SEQ ID NO:8;
- (ii) a sulfo-SPDB linker;
- and
- (iii) a maytansinoid linked to the anti-FOLR1 antibody or antigen-binding fragment thereof by the sulfo-SPDB, and
- (b) an anti-VEGF agent;
- and
- (c) a platinum-based agent.
5 more elements
Dependencies are inferred from the claim text.